LENZ Therapeutics (LENZ) Total Current Liabilities (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Total Current Liabilities of $25.8 million for Q1 2026, up 201.16% year-over-year from $8.6 million in Q1 2025, and up 21.8% quarter-over-quarter from $21.2 million in Q4 2025.
LENZ Therapeutics (LENZ) Total Current Liabilities (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Total Current Liabilities for 7 consecutive years, with $25.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 201.16% year-over-year to $25.8 million; the TTM figure through Mar 2026 stood at $25.8 million (up 201.16% YoY), while the FY2025 annual figure was $21.2 million, up 103.6% from the prior year.
- Total Current Liabilities grew to $25.8 million in Q1 2026 per LENZ's latest filing, from $21.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $25.8 million in Q1 2026 and bottomed at $7.7 million in Q3 2024.
- Historically, Total Current Liabilities has averaged $13.9 million across 5 years, with a median of $12.8 million in 2022.
- Annual changes were most pronounced in 2025 — Total Current Liabilities slumped 54.63% — and 2026, when it soared 201.16%.
- LENZ Therapeutics' Total Current Liabilities stood at $13.0 million in 2022, then soared by 41.95% to $18.5 million in 2023, then sank by 43.79% to $10.4 million in 2024, then soared by 103.6% to $21.2 million in 2025, then advanced by 21.8% to $25.8 million in 2026.
- Business Quant data shows LENZ's Total Current Liabilities at $25.8 million in Q1 2026, $21.2 million in Q4 2025, and $16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 630.93 Mn |
| 10 | LENZ Therapeutics | 149.03 Mn | 149.03 Mn | 5.21 Mn | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.21 Mn |
| Mar 31, 2026 | 25.81 Mn |
| Dec 31, 2025 | 21.19 Mn |
| Sep 30, 2025 | 16.32 Mn |
| Jun 30, 2025 | 10.40 Mn |
| Mar 31, 2025 | 8.57 Mn |
| Dec 31, 2024 | 10.41 Mn |
| Sep 30, 2024 | 7.71 Mn |
| Jun 30, 2024 | 8.58 Mn |
| Mar 31, 2024 | 18.89 Mn |
| Dec 31, 2023 | 18.51 Mn |
| Sep 30, 2023 | 12.54 Mn |
| Jun 30, 2023 | 12.27 Mn |
| Mar 31, 2023 | 14.34 Mn |
| Dec 31, 2022 | 13.04 Mn |
| Sep 30, 2022 | 13.52 Mn |
| Jun 30, 2022 | 12.07 Mn |
| Mar 31, 2022 | 12.77 Mn |
| Dec 31, 2021 | 12.14 Mn |
| Sep 30, 2021 | 11.27 Mn |